Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Correction: End-to-End Approach to Surfactant Selection, Risk Mitigation, and Control Strategies for Protein-Based Therapeutics.

Autor: Morales, Annette Medina, Sreedhara, Alavattam, Buecheler, Jakob, Brosig, Sebastian, Chou, Danny, Christian, Twinkle, Das, Tapan, de Jong, Isabella, Fast, Jonas, Jagannathan, Bharat, Moussa, Ehab M., Nejadnik, M. Reza, Prajapati, Indira, Radwick, Allison, Rahman, Yusra, Singh, Shubhadra

Publikováno v: AAPS Journal; Feb2023, Vol. 25 Issue 1, p1-15, 15p

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

End-to-End Approach to Surfactant Selection, Risk Mitigation, and Control Strategies for Protein-Based Therapeutics.

Autor: Morales AM; Dosage Form Design and Development, BioPharmaceuticals Development, R&D, AstraZeneca, 1 Medimmune Way, Gaithersburg, Maryland, 20878, USA. annette.medina@astrazeneca.com., Sreedhara A; Genentech, Pharmaceutical Development, South San Francisco, California, 94080, USA., Buecheler J; Technical Research and Development, Novartis Pharma AG, 4002, Basel, Switzerland., Brosig S; Technical Research and Development, Novartis Pharma AG, 4002, Basel, Switzerland., Chou D; Compassion BioSolution, LLC, Lomita, California, 90717, USA., Christian T; Amgen, Process Development, Thousand Oaks, California, 91320, USA., Das T; Analytical Development and Attribute Sciences, Bristol Myers Squibb, New Brunswick, New Jersey, USA., de Jong I; Genentech, Pharmaceutical Development, South San Francisco, California, 94080, USA., Fast J; Pharmaceutical Development, F. Hoffmann-La Roche Ltd, CH-4070, Basel, Switzerland., Jagannathan B; Amgen, Process Development, Thousand Oaks, California, 91320, USA., Moussa EM; Drug Product Development, AbbVie, North Chicago, Illinios, 60064, USA., Nejadnik MR; Department of Pharmaceutical Sciences & Experimental Therapeutics, College of Pharmacy, University of Iowa, Iowa City, Iowa, 52242, USA., Prajapati I; Dosage Form Design and Development, BioPharmaceuticals Development, R&D, AstraZeneca, 1 Medimmune Way, Gaithersburg, Maryland, 20878, USA., Radwick A; Symbiotix, New York City, New York, 10016, USA., Rahman Y; Department of Pharmaceutical Sciences & Experimental Therapeutics, College of Pharmacy, University of Iowa, Iowa City, Iowa, 52242, USA., Singh S; GlaxoSmithKline R&D, Biopharmaceutical Product Sciences, Collegeville, Philadelphia, Pennsylvania, 19426, USA.

Publikováno v: The AAPS journal [AAPS J] 2022 Dec 05; Vol. 25 (1), pp. 6. Date of Electronic Publication: 2022 Dec 05.